Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 9/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25729156 | 0.88 | NOS1 (0.42) | CXCR4PRMT5WDR77MC4RMAN1B1 | |
| SCHEMBL19314023 | 0.86 | EED (0.48) | CXCR4PRMT5WDR77SMN1; SMN2 | |
| SCHEMBL20325156 | 0.84 | CXCR4 (0.54) | CXCR4PRMT5WDR77ALDH1A1 | |
| SCHEMBL6450191 | 0.80 | MAN1B1 (0.57) | CXCR4MC4RMAN1B1ALDH1A1ALOX12 | |
| SCHEMBL20324536 | 0.77 | HDAC4 (0.46) | CXCR4MC4RMAN1B1ALDH1A1 | |
| SCHEMBL20325019 | 0.74 | HDAC4 (0.47) | CXCR4ALDH1A1MAPT | |
| SCHEMBL12956919 | 0.74 | PARP1 (0.43) | CXCR4ALDH1A1LMNAMAPTPKM | |
| SCHEMBL21892421 | 0.74 | CXCR4 (0.53) | CXCR4PRMT5WDR77CHRM3 | |
| SCHEMBL20314119 | 0.74 | BCHE (0.52) | SMN1; SMN2 | |
| SCHEMBL20324424 | 0.73 | BCHE (0.54) | SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115339-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115339-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCC1, ABCC3 | CXCR4 629/4885PRMT5 3801/4885WDR77 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.